Targets › M3
3 programs from 2 companies in 5 trials: 5 Phase 2; Ophthalmology.
Open in Phaseline: the race on M3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | BRIMOCHOL PF eye drops Combined alpha-2A adrenergic agonist and muscarinic M3 receptor agonist | ADRA2A, M3 | Phase 2 | Presbyopia | – |
| BioTheraVision | BTV100 Low dose (1% Cevimeline Ophthalmic Solution) M3 muscarinic receptor agonist | M3 | Phase 2 | Dry Eye | – |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | CARBACHOL PF eye drops Muscarinic M3 receptor agonist (cholinergic miotic) | M3 | Phase 2 | Presbyopia | – |
Dry Eye (3) Presbyopia (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.